GlassScriptPhysician profile
Sejal Kadam
NPI 1083659304
$12,281.70
in general payments reported to CMS, 2019-2025
32 companies · $1,857 in 2025
The $1,857 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,966 · 2020: $1,288 · 2021: $1,230 · 2022: $1,498 · 2023: $1,994 · 2024: $2,449 · 2025: $1,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,299.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,425.84 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,209.49 | 2019-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $894.28 | 2023-2025 | Sucraid, Sucraid |
| Redhill Biopharma INC. | $397.08 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $390.45 | 2020-2021 | |
| Intra-Sana Laboratories | $388.98 | 2022-2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Ardelyx, INC. | $346.22 | 2022-2025 | Ibsrela |
| Horizon Therapeutics Plc | $341.41 | 2019-2020 | |
| Genzyme Corporation | $293.87 | 2024-2025 | |
| Novo Nordisk INC | $273.28 | 2024 | |
| Lilly USA, LLC | $254.24 | 2024-2025 | Omvoh, Zepbound |
| Amgen INC. | $243.71 | 2020-2023 | Otezla |
| Janssen Biotech, INC. | $239.36 | 2019-2023 | Simponi, Remicade, Simponi Aria |
| Madrigal Pharmaceuticals | $232.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $177.48 | 2019-2025 | Sutab, Suflave |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $132.89 | 2019-2023 | Dificid |
| Glaxosmithkline, LLC. | $128.36 | 2023 | |
| Celgene Corporation | $125.00 | 2019 | |
| Phathom Pharmaceuticals, INC. | $122.56 | 2023-2024 | Voquezna |
| Ucb, INC. | $122.52 | 2019 | |
| Novartis Pharmaceuticals Corporation | $115.62 | 2019 | |
| Aimmune Therapeutics, INC. | $73.17 | 2025 | Zenpep |
| Vivus LLC | $60.62 | 2023 | Qsymia |
| Ferring Pharmaceuticals INC. | $48.62 | 2022-2023 | Cimzia |
| Intercept Pharmaceuticals, INC. | $45.39 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $45.28 | 2024 | Kristalose |
| Evoke Pharma, INC. | $42.63 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $30.55 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.86 | 2019 | |
| Daiichi Sankyo INC. | $22.06 | 2019 | |
| Valinor Pharma, LLC | $20.09 | 2023 | Movantik |
| Enterra Medical, INC. | $15.66 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sejal Kadam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.